Business Services Industry

NeurAxon, Inc. to Present at 20th Annual Piper Jaffray Health Care Conference December 2, 2008

Business Wire, Nov 18, 2008

WALTHAM, Mass. -- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference taking place December 2-3, 2008 in New York, NY.

The NeurAxon presentation will be delivered on Tuesday, December 2, 2008 at 1:50pm Eastern Time at the New York Palace Hotel.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel, proprietary pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT antagonist which is currently in development for migraine with aura.

About NeurAxon Inc.

NeurAxon Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale